| ZBRA |
Report |
Q2 2026 revenue |
BEAT |
pred ~$1.55B vs. cons $1.53B |
MEDIUM |
| ZBRA |
Report |
Q2 2026 non-GAAP diluted EPS |
BEAT |
pred ~$4.56 vs. cons $4.44 |
MEDIUM |
| ZBRA |
Report |
Q2 2026 adjusted EBITDA margin |
BEAT |
pred ~21.5% vs. cons 21.2% |
LOW |
| ZBRA |
Guide |
FY2026 sales growth |
BETTER |
guide ~12.5% vs. cons 12.3% (FY2026) |
MEDIUM |
| ZBRA |
Guide |
FY2026 non-GAAP diluted EPS |
BETTER |
guide ~$18.90 vs. cons $18.75 (FY2026) |
MEDIUM |
| ZBRA |
Guide |
FY2026 adjusted EBITDA margin |
UNCHANGED |
guide ~22.0% vs. cons 22.0% (FY2026) |
MEDIUM |
| ZBRA |
Return |
Day-1 residual (stock − beta × S&P 500) |
+4.3% |
— |
MEDIUM |
| ZBRA |
Return |
5-day cumulative residual |
+2.6% (FADE) |
Predicted Q2 EPS of ~$4.56 vs. $4.44 consensus supports an initial gain, but FY2026 guidance of ~$18.90 vs. $18.75 consensus implies H2 EPS of approximately $9.59 vs. $9.56 consensus. Near-flat out-period revisions and the strong pre-earnings rally should fade part of the day-1 move. |
MEDIUM |